Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. Based in the NE of England wee have 2 core programmes: PermaLink™ and PermaCarb™. PermaLink™ is a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs) and is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems. PermaCarb™ is a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination.